RXRX
VENTE TOTALE: 82 408 titres (~276 522,38 $ US)
- Insiders
- Khan Najat, Borgeson Blake
- Total bought
- —
- Total sold
- $276,522
- Last activity
- 2026-09-08
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-04
RXRX combines deeply distressed fundamentals (net margin exceeding -800%, persistent cash burn, no path to profitability) with a weak catalyst profile anchored by an insider sale and zero buy-side conviction.
The first sentence of the analysis written for RXRX on 2026-09-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -62.0% | 23.1% | 2.9% | -21.7% | 100.0% | |
| Ebit Margin | -861.1% | -787.3% | -756.7% | -603.4% | -1835.3% | |
| Ebitda Margin | -749.0% | -725.2% | -701.1% | -573.7% | -1751.2% | |
| Operating Profit Margin | -867.9% | -814.1% | -797.8% | -619.3% | -1827.8% | |
| Pretax Profit Margin | -863.5% | -789.9% | -757.0% | -603.5% | -1864.8% | |
| Continuous Operations Profit Margin | -863.4% | -788.0% | -747.7% | -603.5% | -1864.8% | |
| Net Profit Margin | -863.4% | -788.0% | -747.7% | -603.5% | -1864.8% | |
| Bottom Line Profit Margin | -863.4% | -788.0% | -747.7% | -603.5% | -1864.8% | |
| Current Ratio | 5.503 | 3.810 | 4.703 | 5.683 | 11.460 | |
| Quick Ratio | 5.503 | 3.810 | 4.703 | 5.683 | 11.460 | |
| Solvency Ratio | -1.634 | -1.032 | -1.596 | -1.057 | -2.642 | |
| Cash Ratio | 5.032 | 3.170 | 4.203 | 5.485 | 6.111 | |
| Price To Earnings Ratio | -2.840 | -4.000 | -6.241 | -5.669 | -16.314 | |
| Price To Earnings Growth Ratio | 0.192 | -0.575 | -0.386 | -0.192 | -0.163 | |
| Forward Price To Earnings Growth Ratio | 0.192 | -0.575 | -0.386 | -0.192 | -0.163 | |
| Price To Earnings Diluted Ratio | -2.840 | -4.000 | -6.241 | -5.669 | -16.314 | |
| Price To Earnings Diluted Growth Ratio | 0.192 | -0.575 | -0.386 | -0.192 | -0.163 | |
| Price To Book Ratio | 1.618 | 1.791 | 4.422 | 2.786 | 5.372 | |
| Price To Sales Ratio | 24.505 | 31.504 | 46.710 | 34.107 | 291.677 | |
| Price To Free Cash Flow Ratio | -4.838 | -4.971 | -6.824 | -11.196 | -14.701 | |
| Price To Operating Cash Flow Ratio | -4.922 | -5.161 | -7.122 | -16.204 | -18.389 | |
| Debt To Assets Ratio | 0.053 | 0.075 | 0.078 | 0.073 | 0.019 | |
| Debt To Equity Ratio | 0.069 | 0.105 | 0.109 | 0.105 | 0.021 | |
| Debt To Capital Ratio | 0.064 | 0.095 | 0.099 | 0.095 | 0.021 | |
| Long Term Debt To Capital Ratio | 0.008 | 0.018 | 0.002 | 0.001 | 0.001 | |
| Financial Leverage Ratio | 1.304 | 1.400 | 1.411 | 1.444 | 1.124 | |
| Working Capital Turnover Ratio | 0.125 | 0.135 | 0.108 | 0.083 | 0.027 | |
| Operating Cash Flow Ratio | -2.517 | -1.916 | -3.089 | -0.833 | -3.400 | |
| Operating Cash Flow Sales Ratio | -4.979 | -6.104 | -6.559 | -2.105 | -15.861 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.017 | 1.038 | 1.044 | 1.447 | 1.251 | |
| Debt Service Coverage Ratio | -51.302 | -42.572 | -2,199.761 | -1,497.796 | -57.568 | |
| Interest Coverage Ratio | -358.084 | -304.710 | -3,608.866 | -4,467.764 | -61.916 | |
| Short Term Operating Cash Flow Coverage Ratio | -40.898 | -42.632 | -7,019.024 | -861.072 | -1,762.378 | |
| Operating Cash Flow Coverage Ratio | -4.769 | -3.311 | -5.679 | -1.638 | -13.819 | |
| Capital Expenditure Coverage Ratio | -57.475 | -26.227 | -24.072 | -2.236 | -3.985 | |
| Dividend Paid And Capex Coverage Ratio | -57.475 | -26.227 | -24.072 | -2.236 | -3.985 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.082 | -3.205 | -5.554 | -3.753 | -15.093 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -62.0% | ▼-85.1% | ▼-70.5% |
| Ebit Margin | -861.1% | ▼-73.9% | ▲107.6% |
| Ebitda Margin | -749.0% | ▼-23.8% | ▲151.0% |
| Operating Profit Margin | -867.9% | ▼-53.8% | ▲117.5% |
| Pretax Profit Margin | -863.5% | ▼-73.6% | ▲112.2% |
| Continuous Operations Profit Margin | -863.4% | ▼-75.3% | ▲110.1% |
| Net Profit Margin | -863.4% | ▼-75.3% | ▲110.1% |
| Bottom Line Profit Margin | -863.4% | ▼-75.3% | ▲110.1% |
| Current Ratio | 5.503 | ▲1.693 | ▼-0.729 |
| Quick Ratio | 5.503 | ▲1.693 | ▼-0.729 |
| Solvency Ratio | -1.635 | ▼-0.602 | ▼-0.042 |
| Cash Ratio | 5.032 | ▲1.862 | ▲0.232 |
| Price To Earnings Ratio | -2.840 | ▲1.160 | ▲4.173 |
| Price To Earnings Growth Ratio | 0.192 | ▲0.766 | ▲0.417 |
| Forward Price To Earnings Growth Ratio | 0.192 | ▲0.766 | ▲0.417 |
| Price To Earnings Diluted Ratio | -2.840 | ▲1.160 | ▲4.173 |
| Price To Earnings Diluted Growth Ratio | 0.192 | ▲0.766 | ▲0.417 |
| Price To Book Ratio | 1.618 | ▼-0.173 | ▼-1.580 |
| Price To Sales Ratio | 24.505 | ▼-6.999 | ▼-61.195 |
| Price To Free Cash Flow Ratio | -4.838 | ▲0.133 | ▲3.668 |
| Price To Operating Cash Flow Ratio | -4.922 | ▲0.239 | ▲5.437 |
| Debt To Assets Ratio | 0.053 | ▼-0.022 | ▼-0.006 |
| Debt To Equity Ratio | 0.069 | ▼-0.036 | ▼-0.013 |
| Debt To Capital Ratio | 0.065 | ▼-0.030 | ▼-0.010 |
| Long Term Debt To Capital Ratio | 0.008 | ▼-0.010 | ▲0.002 |
| Financial Leverage Ratio | 1.304 | ▼-0.096 | ▼-0.033 |
| Working Capital Turnover Ratio | 0.125 | ▼-0.010 | ▲0.030 |
| Operating Cash Flow Ratio | -2.517 | ▼-0.601 | ▼-0.166 |
| Operating Cash Flow Sales Ratio | -4.979 | ▲1.126 | ▲2.143 |
| Free Cash Flow Operating Cash Flow Ratio | 1.017 | ▼-0.021 | ▼-0.142 |
| Debt Service Coverage Ratio | -51.302 | ▼-8.730 | ▲718.497 |
| Interest Coverage Ratio | -358.084 | ▼-53.374 | ▲1402.184 |
| Short Term Operating Cash Flow Coverage Ratio | -40.898 | ▲1.734 | ▲1904.303 |
| Operating Cash Flow Coverage Ratio | -4.769 | ▼-1.458 | ▲1.074 |
| Capital Expenditure Coverage Ratio | -57.475 | ▼-31.249 | ▼-34.676 |
| Dividend Paid And Capex Coverage Ratio | -57.475 | ▼-31.249 | ▼-34.676 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.082 | ▲1.123 | ▲3.855 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.83B | $1.85B | $2.05B | $1.35B | $2.92B | |
| Enterprise value | $1.16B | $1.37B | $1.71B | $854.5M | $2.64B | |
| EV / Sales | 15.60x | 23.25x | 38.94x | 21.53x | 264.31x | |
| EV / Op. cash flow | -3.13x | -3.81x | -5.94x | -10.23x | -16.66x | |
| EV / Free cash flow | -3.08x | -3.67x | -5.69x | -7.07x | -13.32x | |
| EV / EBITDA | -2.08x | -3.21x | -5.55x | -3.75x | -15.09x | |
| Net debt / EBITDA | 1.19x | 1.14x | 1.11x | 2.19x | 1.56x | |
| Current ratio | 5.50x | 3.81x | 4.70x | 5.68x | 11.46x | |
| Income quality | 0.58x | 0.78x | 0.88x | 0.35x | 0.85x | |
| Graham net-net | $1 | $1 | $1 | $2 | $3 | |
| Tax burden | 100.0% | 99.8% | 98.8% | 100.0% | 100.0% | |
| Interest burden | 100.3% | 100.3% | 100.0% | 100.0% | 101.6% | |
| Working capital | $665.1M | $526.8M | $345.0M | $469.5M | $488.1M | |
| Invested capital | $1.31B | $1.24B | $553.6M | $593.1M | $555.0M | |
| Return on assets | -43.7% | -32.0% | -50.2% | -34.1% | -30.6% | |
| Operating ROA | -44.4% | -45.6% | -51.7% | -37.5% | -40.2% | |
| Return on tangible assets | -64.3% | -48.1% | -58.0% | -34.3% | -30.7% | |
| Return on equity | -57.0% | -44.8% | -70.8% | -49.3% | -34.3% | |
| Return on invested capital | -48.1% | -37.2% | -61.0% | -40.5% | -32.3% | |
| Return on capital employed | -48.9% | -38.0% | -62.5% | -40.9% | -32.4% | |
| Earnings yield | -35.2% | -25.0% | -16.0% | -17.7% | -6.4% | |
| Free cash flow yield | -20.7% | -20.1% | -14.7% | -8.9% | -6.8% | |
| Capex / Op. cash flow | -1.7% | -3.8% | -4.2% | -44.7% | -25.1% | |
| Capex / Depreciation | 7.7% | 37.5% | 49.0% | 317.8% | 473.5% | |
| Capex / Sales | 8.7% | 23.3% | 27.2% | 94.1% | 398.0% | |
| SG&A / Sales | 236.5% | 302.8% | 252.6% | 205.6% | 576.8% | |
| R&D / Sales | 569.4% | 534.4% | 549.8% | 392.4% | 1352.7% | |
| Stock comp / Sales | 148.9% | 138.8% | 121.9% | 70.3% | 148.4% | |
| Intangibles / Total assets | 32.0% | 33.5% | 13.5% | 0.3% | 0.4% | |
| Days sales outstanding | 120d | 305d | 26d | 25d | 332d | |
| Days payables outstanding | 55d | 174d | 34d | 35d | 0d | |
| Operating cycle | 120d | 305d | 26d | 25d | 332d | |
| Cash conversion cycle | 66d | 131d | -8d | -9d | 332d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-1.3%EV / Sales ▼-32.9%EV / EBITDA ▲+35.0%EV / Op. cash flow ▲+0.676Earnings yield ▼-0.102
Profitability
Return on equity ▼-0.122Return on assets ▼-0.117Return on invested capital ▼-0.108Return on capital employed ▼-0.109Operating ROA ▲+0.012Income quality ▼-0.198Tax burden ▲+0.002
Efficiency
Days sales outstanding ▼-184.524Days payables outstanding ▼-119.709Operating cycle ▼-184.524Cash conversion cycle ▼-64.815Capex / Sales ▼-0.146R&D / Sales ▲+0.351
Balance-sheet strength
Current ratio ▲+1.693Net debt / EBITDA ▲+0.051Working capital ▲+138341000.000Invested capital ▲+61941000.000Intangibles / Total assets ▼-0.014
Change over 5 years
Valuation
Market cap ▼-37.3%EV / Sales ▼-94.1%EV / EBITDA ▲+86.2%EV / Op. cash flow ▲+13.531Earnings yield ▼-0.288
Profitability
Return on equity ▼-0.227Return on assets ▼-0.132Return on invested capital ▼-0.157Return on capital employed ▼-0.164Operating ROA ▼-0.041Income quality ▼-0.274Tax burden -0.000
Efficiency
Days sales outstanding ▼-211.314Days payables outstanding n/aOperating cycle ▼-211.314Cash conversion cycle ▼-265.988Capex / Sales ▼-3.893R&D / Sales ▼-7.833
Balance-sheet strength
Current ratio ▼-5.957Net debt / EBITDA ▼-0.373Working capital ▲+177078000.000Invested capital ▲+751708000.000Intangibles / Total assets ▲+0.317
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-10 Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day''s close.
- 2026-09-08 2 Beaten-Down Stocks to Avoid Right Now Don''t catch a falling knife.
- 2026-09-04 Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What''s next for the stock?
- 2026-09-03 The Market Just Told You Which Layer Of AI Biology It Is Paying For AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry''s data and systems of record beat and jumped. The company selling model-informed software into the same customers missed and fell by roughly the same amount on the day.
- 2026-09-03 Can RXRX''s Pipeline Expansion Strengthen Its Long-Term Growth Outlook? Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
- 2026-08-17 4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
- 2026-08-17 Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates Recursion Pharmaceuticals (NASDAQ: RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference. Taylor described AI not as a "magic wand,"
- 2026-08-17 Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference.
- 2026-08-13 Recursion Pharmaceuticals, Inc. $RXRX Stake Increased by California State Teachers Retirement System California State Teachers Retirement System lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 64.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 574,637 shares of the company''s stock after buying an additional 224,332 shares during the period.
- 2026-08-11 Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript